Latest news with #SanjayVyas
Time of India
3 days ago
- Time of India
Patidar women in Morbi barred from joining mixed-gender garba classes
Rajkot: In an unprecedented diktat in the run-up to Navratri, the Patidar community in the ceramic town of Morbi has prohibited its women from joining co-ed garba training classes so that 'notorious' elements don't exploit the 'innocence' of females. Tired of too many ads? go ad free now A resolution to the effect was passed with majority support at a massive congregation of various Patidar associations organised on Aug 2, attended by thousands, including politicians and local MLAs. Patidars, who account for nearly 70% of Morbi's population, have also directed the garba organisers not to open classes in areas such as Ravapar Road, Patel Nagar, SP Road, and Alap Society, where the community resides in significant numbers. Justifying the decision, Manoj Panara, president of Patidar Yuva Sena Sangh, told TOI, "This decision was taken after reports that some men joined garba classes only to target young women. When men and women dance together to love songs for three months in garba classes, it's natural that they may get attracted to each other. Some notorious people join these classes only to woo girls and exploit their innocence." As an alternative, the community has started women-only garba training centres at five locations, including Kanya Chatralay, Patel Nagar, Vaibhav Nagar, and Ravapar Road. The academies have been strictly told to employ only female choreographers for women, have separate training timings for men and women, and verify the identity of trainers and participants, considering the safety of the women of other communities who also join these classes. Sanjay Vyas, president of the Morbi Garba Classes Association, lamented the financial loss but said the organisers have agreed to comply. "They are in the majority, and we are all connected in business. Tired of too many ads? go ad free now We don't want to take responsibility if anything adverse happens," he said. There are 27 garba classes in Morbi, with a majority of them starting three months before Navratri, while around seven classes teach garba and other dance forms throughout the year. The associations have not explicitly spelt out how they would deal with violations of the rules, but said their members will meet the parents of the women flouting the decision and counsel them.
Time of India
09-07-2025
- Business
- Time of India
Trials to Talent, Mohali to Market: Inside Parexel's GCC Strategy
In this episode of The GCC Show, we take you inside the dynamic world of life sciences and clinical research with a leader who has been instrumental in scaling global operations from India. Joining us is Sanjay Vyas, President and Managing Director of Parexel India, a company with experience in clinical research and regulatory services, playing a pivotal role in bringing new treatments to market. Parexel's GCC in India is more than just a support engine—it's a hub for innovation, and transformative talent. With investments in Mohali and a sharp focus on operational resilience, Parexel is redefining what it means to deliver global healthcare solutions from India. Advertisement Tune in as we explore: The strategic story behind Parexel's India GCC; How innovation is reshaping clinical research operations; Why Mohali matters—and its rising role in the region's talent economy; What's next for healthcare, life sciences, and global delivery from India.
Khaleej Times
26-02-2025
- Health
- Khaleej Times
India on the verge of becoming clinical trials hub, says Parexel executive
India is ready to step in as an alternative site for early-stage clinical trials to help mitigate the impact of disruptions such as the Russia-Ukraine war, an executive at contract research firm Parexel told Reuters on Wednesday. The US-based company plans to boost its headcount in India by more than 2,000 over the next three to five years, from about 6,000 currently, said Sanjay Vyas, who heads Parexel's India operations. Vyas said India is well-placed to attract clinical trials disrupted by geopolitical conflicts such as the Russia-Ukraine war, as well as efforts by global drugmakers to reduce reliance on China. Ukraine, along with Russia, had become important countries for studying new drugs before Russia's attack in 2022. In subsequent years, however, large companies and researchers have reported disruptions to trials there. Vyas said Parexel plans to hire for roles that could help build innovation hubs. "Because the cost of failure in India is much less than in other parts of the world," he said on the sidelines of the ongoing BioAsia conference in the southern state of Telangana. Durham, North Carolina-headquartered Parexel, among the world's top clinical research organisations, operates between 100 and 150 trial sites in India, located across states including Maharashtra, Karnataka, Telangana and Tamil Nadu. India's clinical trials data market is estimated to touch $1.51 billion in 2025, according to US-based GrandView Research. While India's reputation as a trusted region for conducting trials is improving, several challenges, such as a lack of standardised regulations for some early-stage studies, remain before it can become a top choice for drugmakers. "If you don't do phase 1 trials, the same patient will have to wait for a phase 3 (late-stage) trial to happen for the drug to come into the market. So you have the time lost, which you could have gotten earlier on if the molecule was already introduced in advance," Vyas said. He also highlighted a lack of awareness about experimental treatments among patients and doctors, as well as establishing trial sites in remote areas, as other challenges in India.
